Vivatides Therapeutics (蔚程医药)

Suzhou–Boston siRNA/ASO startup building ligand-conjugate delivery to take oligonucleotide drugs beyond the liver.

1. Core Product / Service

Vivatides is developing an extrahepatic delivery platform for oligonucleotide drugs — ligand conjugates that carry both siRNA and antisense oligonucleotides (ASO) to tissues other than the liver [1][3]. GalNAc conjugation solved liver delivery and underpins most approved RNAi drugs; reaching muscle, CNS, adipose, kidney or tumor tissue is the field's main open problem. The company says it has in vivo data supporting the platform, but specific targets and programs are undisclosed and all programs are preclinical; Series A money funds IND-enabling work [1][3][6].

2. Target Users & Pain Points

Patients with diseases driven by genes expressed outside the liver, for which infrequently-dosed oligonucleotides are not yet possible.
Pharma partners that already own liver RNAi franchises and want a second-generation delivery chemistry. The press release cites hyperlipidemia, hypertension and oncology as context, but these are field-level examples, not named company programs [1][3].

3. Competitive Landscape

Player	Positioning	Vs. Vivatides
Global RNAi leaders (Alnylam, Arrowhead, Ionis, Dicerna/Novo)	Own GalNAc liver franchises; pushing CNS, muscle, adipose and lung delivery	Far larger and clinical; Vivatides' team is drawn from these companies
Chinese siRNA companies founded 2021–2022 (e.g. 舶望, 圣因, 炫景, 赫吉亚)	Mostly liver-targeted siRNA, several clinical	Larger rounds and further along; Vivatides bets on extrahepatic only [1]
weitao-bio	Another 2025 Chinese nucleic-acid startup backed by Qiming and Apricot	LNP-mRNA rather than conjugated oligos

4. Unique Observations

Cross-border by design: dual headquarters in Suzhou and Woburn/Boston, and one English-language database calls it a Hong Kong startup — likely an offshore holding structure (inference) [1][4]. It is the clearest example in its cohort of a China-cost, US-facing model built from day one [2].
Pedigree financing: seed plus Series A (US$64M) closed within about a year, on the strength of a team described as coming from Arrowhead, Ionis, Alnylam and Dicerna with experience on clinical-stage extrahepatic RNA programs (press-release summary; individuals not named) [1][3].
Wet-lab model (unconfirmed): no job postings or lab disclosures were found. A plausible split is oligo chemistry and animal studies in Suzhou, where lab rent is a fraction of Boston's, with BD and clinical strategy in the US — not verified [1][7]. For Chinese GalNAc-siRNA programs, BCG estimates cost-to-candidate at roughly US$4–7M, 2.5–3.5x cheaper in China than the US [7].

5. Financials / Funding

Round	Date	Amount	Investors
Seed	2025-08	US$10M	Apricot Capital (lead), Qiming [1][5]
Series A	2026-04-10	US$54M (oversubscribed)	Qiming and an unnamed industry fund (co-leads); Highlight Capital, TF Capital; Apricot Capital (follow-on) [3][6]

Total: US$64M [1].
Use of proceeds: platform expansion, moving programs toward the clinic, building a global team and R&D network [3].

6. People & Relationships

Founder & CEO: Keming Zhou (personal background not disclosed) [3][6].
Founded: 2025 [3].
Investors: Qiming Venture Partners, Apricot Capital, Highlight Capital, TF Capital.
Peers: weitao-bio, scibrunch, allink-biotherapeutics, yili-pharma.